A groundbreaking experimental drug for hepatitis B, developed by GSK and Ionis Pharmaceuticals, is showing promise in providing a ‘functional cure’ for some patients, allowing them to stop treatment without the virus reemerging. This development could significantly impact the lives of those suffering from chronic hepatitis B, a condition that can lead to severe liver damage and affects millions worldwide.
Promising Results from International Studies
In two international studies, approximately 20% of patients who received the drug, known as bepirovirsen or ‘bepi,’ experienced a reduction in the virus to levels that the immune system could manage without ongoing treatment. This is a significant advancement, as current therapies require lifelong adherence and can be difficult to access in certain regions.
Dr. Seng Gee Lim of the National University Health System of Singapore, a leader in the studies funded by GSK, highlighted the unprecedented level of cure achieved by this treatment. The findings were presented at a scientific meeting in Barcelona and published in the New England Journal of Medicine.
Understanding Hepatitis B and the New Treatment
Hepatitis B is a serious liver infection spread through contact with infected blood or bodily fluids. While a vaccine exists, those who contract the virus may develop a chronic form that progressively damages the liver. Traditional treatments focus on reducing viral levels to prevent liver damage, but a complete cure has been elusive due to the virus’s ability to hide within the body.
Bepi works by binding to the virus’s genetic material, suppressing its replication and stimulating the immune system. In trials involving 1,838 patients, those who received bepi showed a higher likelihood of achieving a functional cure compared to those who received a placebo.
Next Steps and Considerations
The U.S. Food and Drug Administration is currently reviewing bepi under a fast-track process, with a decision expected in October. Regulatory bodies in Japan, China, and Europe are also evaluating the drug. While the results are promising, experts like Dr. Anna Lok from the University of Michigan caution that further research is needed to determine the long-term efficacy of the treatment.
Side effects reported during the trials were generally mild, including temporary redness at the injection site and a rise in liver enzymes, indicating potential liver stress. The trials did not include patients with more severe conditions such as cirrhosis, which will need to be addressed in future studies.
This development represents a hopeful step forward in the fight against hepatitis B, offering a potential new avenue for those affected by this chronic illness.
Original reporting: Dallas TX News (HLL/CB) — read the source article.
